Overview and Scope
The narcolepsy drugs market consists of sales of orexin receptor antagonists, stimulants, and orexin-based therapy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Sizing and Forecast
The narcolepsy drugs market size has grown strongly in recent years. It will grow from $3.31 billion in 2023 to $3.62 billion in 2024 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to increased awareness and diagnosis, improved treatment options, regulatory approvals, growing awareness and diagnosis rates, and expansion of healthcare services.
The narcolepsy drugs market size is expected to see strong growth in the next few years. It will grow to $5.23 billion in 2028 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to the rising prevalence of sleep disorders, advances in personalized medicine, an aging population with increased susceptibility to sleep disorders, increasing enhanced patient support and assistance programs, and expanding healthcare coverage. Major trends in the forecast period include technological innovations, pharmaceutical companies continuing patient-centric approaches, research and development in biologic therapies, innovative drug formulations, and a shift towards non-stimulant alternatives.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/narcolepsy-drugs-global-market-report
Segmentation & Regional Insights
The narcolepsy drugs market covered in this report is segmented –
1) By Type: Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy, Secondary Narcolepsy
2) By Disease: Daytime Extreme Sleepiness, Cataplexia, Other Diseases
3) By Therapeutic: Sodium Oxybate, Central Nervous System Stimulants, Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitor, Other Therapeutics
North America was the largest region in the narcolepsy drugs market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the narcolepsy drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16490&type=smp
Major Driver Impacting Market Growth
The growing demand for personalized medicine is expected to propel the growth of the narcolepsy drugs market going forward. Personalized medicine refers to a medical care philosophy that aims to tailor medicines and interventions to the particular requirements of each patient. The demand for personalized medicine is due to the rapid growth of omics technology, data integration, genetics, and an awareness of the significance of tailored patient-specific medications and preventive actions. Narcolepsy drugs are used in personalized medicine for tailoring treatment plans to individual patient needs, considering genetic profiles, symptom severity, metabolic rates, and personal preferences to optimize effectiveness and minimize side effects. For instance, according to the Personalized Medicine Coalition, a US-based professional organization, around 12 new customized medications were approved in 2022, accounting for around 34% of all newly approved treatments compared to 2021. Therefore, the growing demand for personalized medicine drives the growth of the narcolepsy drugs market.
Key Industry Players
Major companies operating in the narcolepsy drugs market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., UCB SA, Sun Pharmaceutical Industries Ltd., Jazz Pharmaceutical plc, Ipsen Group, Lundbeck AS, Hikma Pharmaceuticals plc, Lupin Limited, Viatris Inc., Harmony Biosciences Holdings Inc., Ligand Pharmaceuticals Incorporated, Sumitomo Dainippon Pharma Co. Ltd., Avadel Pharmaceuticals plc, Bioprojet Pharma s.a.r.l, Graymark Healthcare Inc., Flamel Technologies SA, Arena Pharmaceuticals
The narcolepsy drugs market report table of contents includes:
1. Executive Summary
- Narcolepsy Drugs Market Characteristics
- Narcolepsy Drugs Market Trends And Strategies
- Narcolepsy Drugs Market – Macro Economic Scenario
- Global Narcolepsy Drugs Market Size and Growth
.
- Global Narcolepsy Drugs Market Competitive Benchmarking
- Global Narcolepsy Drugs Market Competitive Dashboard
- Key Mergers And Acquisitions In The Narcolepsy Drugs Market
- Narcolepsy Drugs Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
